Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biocryst Pharma Inc (NQ: BCRX )

12.79 -0.17 (-1.31%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 2, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,836,167
Open 12.82
Bid (Size) 12.57 (1)
Ask (Size) 12.91 (10)
Prev. Close 12.96
Today's Range 12.69 - 12.93
52wk Range 7.610 - 19.99
Shares Outstanding 185,583,896
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
BioCryst Pharmaceuticals Stock Sees RS Rating Rise To 84
The Relative Strength (RS) Rating for BioCryst Pharmaceuticals stock climbed into a new percentile Friday, with a rise from 64 to 84. 
Via Investor's Business Daily
Expert Ratings for BioCryst Pharmaceuticals
Analysts have provided the following ratings for BioCryst Pharmaceuticals (NASDAQ:BCRX) within the last quarter: 
Via Benzinga

Performance

YTD
-9.10%
-9.10%
1 Month
+6.41%
+6.41%
3 Month
-9.10%
-9.10%
6 Month
+22.39%
+22.39%
1 Year
+7.70%
+7.70%

More News

Read More
4 Analysts Have This to Say About BioCryst Pharmaceuticals
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2022
Via Benzinga
BioCryst Pharmaceuticals (BCRX) Q3 2022 Earnings Call Transcript
Via The Motley Fool
Why Harsco Shares Surged Over 22%; Here Are 80 Biggest Movers From Yesterday
Via Benzinga
Why Abiomed Shares Are Trading Higher By Over 50%? Here Are 60 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Goodyear Tire, Catalent, Zebra Technologies And Some Other Big Stocks Moving Lower On Tuesday
Via Benzinga
What's Going On With BioCryst Pharmaceuticals Stock Today?
Via Benzinga
BioCryst Pharmaceuticals: Q3 Earnings Insights
Via Benzinga
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
Via Investor's Business Daily
BioCryst Pharmaceuticals Stock Shows Rising Relative Strength
Via Investor's Business Daily
Kalvista Crashes Nearly 60% After Adding HAE Drug To The Scrap Heap
Via Investor's Business Daily
3 Biotech Stocks to Buy Now for Extraordinary Gains
Via InvestorPlace
BioCryst Secures FDA Orphan Drug Status For Rare Connective Tissue Disease Candidate
Via Benzinga
Recap Of Friday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
BioCryst Exhibits Positive Data From Early-Stage Rare Kidney Disease Study
Via Benzinga
US Government To Purchase Additional Influenza Treatment From BioCryst For Pandemic Preparedness
Via Benzinga
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Novavax, Upstart Holdings And Some Other Big Stocks Moving Lower In Today's Pre-Market Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022
Via Benzinga
Coinbase, MercadoLibre And Some Other Big Stocks Recording Gains On Thursday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2022
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Why NanoViricides Jumped Over 48%; Here Are 106 Biggest Movers From Yesterday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.